Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples